Sarepta Therapeutics (SRPT) Gross Margin (2017 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Gross Margin of 85.12% for Q1 2026, up 8829.0% year-over-year from 0.95% in Q1 2025, and up 752.46% quarter-over-quarter from 9.98% in Q4 2025.
Sarepta Therapeutics (SRPT) Gross Margin (2017 - 2026) Analysis & Trends
Sarepta Therapeutics' Gross Margin history runs 10 years deep, the most recent figure standing at 85.12% for Q1 2026.
- In Q1 2026, Gross Margin rose 8829.0% year-over-year to 85.12%; the TTM figure through Mar 2026 stood at 62.88% (down 1208.0% YoY), while the FY2025 annual figure was 54.96%, down 2826.0% from the prior year.
- Gross Margin for Q1 2026 stood at 85.12%, up from 9.98% in the prior quarter.
- The five-year high for Gross Margin was 96.44% in Q4 2022, with the low at 3.17% in Q1 2025.
- The 5-year median for Gross Margin is 83.35% (2022), against an average of 74.43%.
- The sharpest annual moves came in 2025 and 2026: Gross Margin slumped 9095 bps in 2025, then jumped 8829 bps in 2026.
- Sarepta Therapeutics' Gross Margin stood at 96.44% in 2022, then decreased by 1 bps to 95.9% in 2023, then decreased by 17 bps to 79.91% in 2024, then sank by 88 bps to 9.98% in 2025, then jumped by 752 bps to 85.12% in 2026.
- Business Quant data shows SRPT's Gross Margin at 85.12% in Q1 2026, 9.98% in Q4 2025, and 62.25% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 90.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 89.76% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 60,631,834.75% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 76.90% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 84.20% |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn | 62.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 62.77% |
| Mar 31, 2026 | 85.12% |
| Dec 31, 2025 | 9.98% |
| Sep 30, 2025 | 62.25% |
| Jun 30, 2025 | 75.04% |
| Mar 31, 2025 | -3.17% |
| Dec 31, 2024 | 79.91% |
| Sep 30, 2024 | 80.37% |
| Jun 30, 2024 | 87.73% |
| Mar 31, 2024 | 87.77% |
| Dec 31, 2023 | 95.90% |
| Sep 30, 2023 | 88.03% |
| Jun 30, 2023 | 86.94% |
| Mar 31, 2023 | 84.87% |
| Dec 31, 2022 | 96.44% |
| Sep 30, 2022 | 82.65% |
| Jun 30, 2022 | 82.11% |
| Mar 31, 2022 | 83.35% |
| Dec 31, 2021 | 82.24% |
| Sep 30, 2021 | -4.22% |